At a glance
ClinicalIndex Comparison RecordN/AUnknown· 70 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer ( Poseidon Study）
In Brief
An observational study for Non-small Cell Lung Cancer. Targeting 70 participants across 1 site.
Detailed Summary
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
N/AUnknownOverdue
202120222023202420252026
Enrollment StartMar 2020
First PostedMar 2020
Primary CompletionDec 2024
Study CompletionMar 2025
TodayJul 2026
First PostedMar 26, 2020
Enrollment StartMar 24, 2020
Primary CompletionDec 24, 2024
Study CompletionMar 24, 2025
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 6.3 years ago